4583 Stock Overview
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Chiome Bioscience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥122.00 |
| 52 Week High | JP¥234.00 |
| 52 Week Low | JP¥117.00 |
| Beta | 0.81 |
| 1 Month Change | -8.96% |
| 3 Month Change | -12.23% |
| 1 Year Change | -43.78% |
| 3 Year Change | -43.78% |
| 5 Year Change | -34.41% |
| Change since IPO | -58.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4583 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -0.8% | -5.0% | -0.4% |
| 1Y | -43.8% | -36.3% | 27.4% |
Return vs Industry: 4583 underperformed the JP Life Sciences industry which returned -36.3% over the past year.
Return vs Market: 4583 underperformed the JP Market which returned 27.4% over the past year.
Price Volatility
| 4583 volatility | |
|---|---|
| 4583 Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4583's share price has been volatile over the past 3 months.
Volatility Over Time: 4583's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shigeru Kobayashi | www.chiome.co.jp |
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, a chicken antibody gene converted to humanized antibodies.
Chiome Bioscience Inc. Fundamentals Summary
| 4583 fundamental statistics | |
|---|---|
| Market cap | JP¥7.02b |
| Earnings (TTM) | -JP¥1.22b |
| Revenue (TTM) | JP¥682.46m |
10.0x
P/S Ratio-5.6x
P/E RatioIs 4583 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4583 income statement (TTM) | |
|---|---|
| Revenue | JP¥682.46m |
| Cost of Revenue | JP¥283.87m |
| Gross Profit | JP¥398.60m |
| Other Expenses | JP¥1.62b |
| Earnings | -JP¥1.22b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -21.71 |
| Gross Margin | 58.41% |
| Net Profit Margin | -178.77% |
| Debt/Equity Ratio | 25.1% |
How did 4583 perform over the long term?
See historical performance and comparison